Cordant Inc’s Nektar Therapeutics NKTR Stock Holding History

Cordant Inc’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6	Closed	-$1K	–	846
2022 Q1	$1K	Buy	+6	New	+$888	﹤0.01%	1033

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Cordant Inc's NKTR Position: Q2 2022 in Review

Cordant Inc sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 6 shares — an estimated $1K sold.

Cordant Inc first reported a position in NKTR in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Cordant Inc reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 6 Nektar Therapeutics shares in Q2 2022, an estimated $1K.
Cordant Inc first reported a position in Nektar Therapeutics in Q1 2022 and held it in 1 quarter.
Cordant Inc's Nektar Therapeutics position peaked at $1K in Q1 2022.
227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.